Wolverine Trading
ESPR

Wolverine Trading’s Esperion Therapeutics ESPR Stock Holding History

Wolverine Trading’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,805
Closed -$20.9K – 5770
2025
Q2 		$10.7K Buy
+10,805
New +$10.8K ﹤0.01% 4494
2024
Q4 		– Sell
-10,969
Closed -$25.6K – 5408
2024
Q3 		$18.4K Buy
+10,969
New +$22.1K ﹤0.01% 4644
2018
Q3 		– Sell
-26,079
Closed -$1.89M – 5155
2018
Q2 		$1.89M Hold
26,079
– – ﹤0.01% 1643
2018
Q1 		$1.89M Buy
26,079
+16,878
+183% +$1.24M ﹤0.01% 1643
2017
Q4 		$606K Buy
+9,201
New +$495K ﹤0.01% 2776
2017
Q3 		– Sell
-11,155
Closed -$538K – 4567
2017
Q2 		$527K Buy
+11,155
New +$410K ﹤0.01% 2381

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $780M AUM 24.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Wolverine Trading's ESPR Position: Q3 2025 in Review

Wolverine Trading sold out of Esperion Therapeutics (ESPR) in Q3 2025, closing a stake of 10,805 shares — an estimated $20.9K sold.

Wolverine Trading first reported a position in ESPR in Q2 2017 and held it in 6 quarters. The position peaked at $1.89M in Q2 2018. 188 funds tracked by Wall St. Rank hold ESPR as of Q3 2025.

  • Wolverine Trading reported no remaining Esperion Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Wolverine Trading sold 10,805 Esperion Therapeutics shares in Q3 2025, an estimated $20.9K.
  • Wolverine Trading first reported a position in Esperion Therapeutics in Q2 2017 and held it in 6 quarters.
  • Wolverine Trading's Esperion Therapeutics position peaked at $1.89M in Q2 2018.
  • 188 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2025.

Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.